Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Angle PLC - Guildford, England-based liquid biopsy company - Announces new contract with clinical-stage biotechnology company Artios Pharma for use of two DNA damage response assays in a Phase 1 clinical trial. Artios was Angle’s first bespoke assay development customer, selecting it to develop immunofluorescence assays to detect biomarkers on tumour cells. The Phase 1 trial will begin ‘shortly’ with completion expected around the end of 2024. Angle says the assays could later be used in larger and later-stage clinical trials.
Chief Executive Andrew Newland says: ‘This new contract for clinical trial services again represents significant repeat business from an existing customer, and we believe there is potential to expand the relationship further. These new assays also provide an important addition to our pharma services menu, where our unique solution has already generated a high level of interest from new potential customers.’
Current stock price: 18.36 pence, down 0.8% in London on Thursday afternoon
12-month change: down 88%
Copyright 2023 Alliance News Ltd. All Rights Reserved.